The current price of RARE is $15.57 — it has decreased by 9.27% since the previous close. Data as of Nov 5, 2026.
RARE is down 6.43% over the past week, up 7.38% over the past month and down 51.15% over the past year. The price is below its 200-day moving average of $22.80.
Analysts' average 12-month price target for RARE is $25.54, which implies 64.03% upside from the current price. Individual estimates range from $16.00 to $39.00.
Of the 21 analysts covering Ultragenyx Pharmaceutical Inc., 2 rate it a strong buy, 8 rate it a buy and 11 rate it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
Ultragenyx Pharmaceutical Inc. has a market capitalization of $1.54B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Ultragenyx Pharmaceutical Inc. posted a loss of $1.16 per share against an estimate of -$1.10, missing expectations by 5.45%. Upcoming reports are listed in the earnings calendar.
Ultragenyx Pharmaceutical Inc. reported revenue of $173M in its most recent quarter, which has increased by 8.17% compared with the same quarter a year earlier. Analysts had expected $182.49M.
Companies most comparable to Ultragenyx Pharmaceutical Inc. include BridgeBio Pharma, Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics, Inc., uniQure N.V. and MeiraGTx Holdings plc.
In the latest trading session RARE moved between $15.49 and $17.12, a range of 10.45% of its current price.
Over the past 52 weeks RARE has traded between $12.73 and $39.89. The current price is 60.97% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.